Gritstone bio, Inc.: directors' dealings · United States · SEC (Form 4)

About Gritstone bio, Inc.

Gritstone bio, Inc. (ticker: GRTS) is a United States biotechnology company listed on the NASDAQ market. The company was founded in August 2015 and has been associated with Emeryville, California, in the San Francisco Bay Area. Gritstone’s business has been built around a highly specialized oncology and immunology thesis: developing next-generation immunotherapies and vaccines designed to target cancer and infectious disease. For equity investors, the company fits squarely within the clinical-stage biotech universe, where scientific differentiation matters, but capital intensity, regulatory execution, and financing risk are often decisive. Operationally, Gritstone has focused on vaccine-based and immunotherapy-based programs, particularly around tumor-specific peptide-HLA (pMHC) targets and neoantigen-oriented approaches. That scientific positioning aims to improve precision in cancer targeting and to support differentiated immune responses. The company has also communicated work in infectious-disease vaccine development, although its public narrative has increasingly emphasized oncology R&D. In practical terms, Gritstone has been a platform-driven biotech rather than a commercial-stage pharmaceutical company, meaning its value creation depends primarily on preclinical and clinical milestones, intellectual property, and the ability to advance candidates through the development pathway. The company’s corporate history is important for investors. It was originally incorporated as a Delaware corporation in 2015 and later changed its name from Gritstone Oncology, Inc. to Gritstone bio, Inc. in 2021, reflecting a broader scope beyond oncology alone. Its geographic base has been tied to the California biotech ecosystem, which provides proximity to research talent, venture capital, and partner networks. However, the company also experienced severe financial stress: in October 2024 it filed for Chapter 11 protection in the United States, and in April 2025 it emerged as a leaner organization focused solely on research and development of its oncology technologies. From a competitive standpoint, Gritstone operates in a crowded and scientifically demanding segment that includes larger immuno-oncology, vaccine, and precision-medicine developers with greater financial resources. Its competitive strengths are its technological focus, niche intellectual property, and ongoing research output, including 2025 patent-related announcements. Its weaknesses are equally clear: limited scale, restructuring history, and dependence on clinical and financing outcomes. As a result, GRTS should be viewed as a high-risk NASDAQ biotechnology name in the United States, tracked less for stable operating cash flow and more for pipeline progress, insider activity reported through Form 4 filings, and corporate restructuring developments.